STEM CELL MOBILIZATION IN PATIENTS WITH NEWLY DIAGNOSED MULTIPLE MYELOMA FOLLOWING THERAPY WITH LENALIDOMIDE AND DEXAMETHASONE

被引：0
|
作者：
Kumar, S. [1 ]
Lacy, M. Q. [1 ]
Dispenzieri, A. [1 ]
Hayman, S. R. [1 ]
Dingli, D. [1 ]
Miceli, T. [1 ]
Litzow, M. R. [1 ]
Rajkumar, S. V. [1 ]
Gertz, M. A. [1 ]
机构：
[1] Mayo Clin, Rochester, MN USA
来源：
BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION | 2009年 / 15卷 / 02期
关键词：
D O I：
10.1016/j.bbmt.2008.12.205
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
177
引用
收藏
页码：66 / 66
页数：1
相关论文
共 50 条
  • [41] Bortezomib washout duration prior to stem cell mobilization in patients with newly diagnosed multiple myeloma
    Luttwak, Efrat
    Amit, Odelia
    Avivi, Irit
    Trestman, Svetlana
    Eshel, Rinat
    Cohen, Yael C.
    Ram, Ron
    [J]. EUROPEAN JOURNAL OF HAEMATOLOGY, 2020, 105 (01) : 30 - 34
  • [42] A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma
    Khan, Meaghan L.
    Reeder, Craig B.
    Kumar, Shaji K.
    Lacy, Marthy Q.
    Reece, Donna E.
    Dispenzieri, Angela
    Gertz, Morie A.
    Greipp, Phillip
    Hayman, Suzanne
    Zeldenhurst, Steven
    Dingli, David
    Lust, John
    Russell, Stephen
    Laumann, Kristina M.
    Mikhael, Joseph R.
    Bergsagel, P. Leif
    Fonseca, Rafael
    Rajkumar, S. Vincent
    Stewart, A. Keith
    [J]. BRITISH JOURNAL OF HAEMATOLOGY, 2012, 156 (03) : 326 - 333
  • [43] Front-line lenalidomide therapy in patients with newly diagnosed multiple myeloma
    Cejalvo, Maria J.
    de la Rubia, Javier
    [J]. FUTURE ONCOLOGY, 2015, 11 (11) : 1643 - 1658
  • [44] Daratumumab, bortezomib, lenalidomide, and dexamethasone (DVRd) vs daratumumab, carfilzomib, lenalidomide and dexamethasone (DKRd) as induction therapy in newly diagnosed multiple myeloma
    Tan, Carlyn Rose
    Maclachlan, Kylee
    Nemirovsky, David
    Derkach, Andriy
    Hultcrantz, Malin
    Hassoun, Hani
    Mailankody, Sham
    Shah, Urvi
    Patel, Dhwani
    Shekarkhand, Tala
    Rueda, Colin
    Lahoud, Oscar
    Shah, Gunjan
    Scordo, Michael
    Chung, David
    Landau, Heather
    Giralt, Sergio
    Usmani, Saad
    Lesokhin, Alexander
    Korde, Neha
    [J]. CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S127 - S127
  • [45] Lenalidomide, doxorubicin hydrochloride and dexamethasone versus bortezomib, lenalidomide, and dexamethasone prior to scheduled stem cell transplant in newly diagnosed myeloma.
    Knop, Stefan
    Langer, Christian
    Engelhardt, Monika Martha
    Wangemann, Johanne
    Muegge, Lars Olof
    Bassermann, Florian
    Schaefer-Eckart, Kerstin
    Blau, Igor W.
    Wolleschak, Denise
    Reichle, Albrecht
    von Metzler, Ivana
    Metzner, Bernd
    Rollig, Christoph
    Hertenstein, Bernd
    Pfreundschuh, Michael
    Brummendorf, Tim H.
    Gramatzki, Martin
    Ritgen, Mattias
    Held, Swantje
    Einsele, Hermann
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [46] Impact of lenalidomide therapy on stem cell mobilization in myeloma
    Paripati, H.
    Stewart, A. K.
    Fonseca, R.
    Dueck, A. C.
    Slack, J. L.
    Reeder, C. B.
    Leis, J.
    Bergsagel, P. L.
    Torloni, A. S.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2008, 26 (15)
  • [47] Oral ixazomib, lenalidomide, and dexamethasone for transplant-ineligible patients with newly diagnosed multiple myeloma
    Facon, Thierry
    Venner, Christopher P.
    Bahlis, Nizar J.
    Offner, Fritz
    White, Darrell J.
    Karlin, Lionel
    Benboubker, Lotfi
    Rigaudeau, Sophie
    Rodon, Philippe
    Voog, Eric
    Yoon, Sung-Soo
    Suzuki, Kenshi
    Shibayama, Hirohiko
    Zhang, Xiaoquan
    Twumasi-Ankrah, Philip
    Yung, Godwin
    Rifkin, Robert M.
    Moreau, Philippe
    Lonial, Sagar
    Kumar, Shaji K.
    Richardson, Paul G.
    Rajkumar, S. Vincent
    [J]. BLOOD, 2021, 137 (26) : 3616 - 3628
  • [48] Phase 2 Trial of Ixazomib, Lenalidomide, Dexamethasone and Daratumumab in Patients with Newly Diagnosed Multiple Myeloma
    Kumar, Shaji K.
    Kapoor, Prashant
    Laplant, Betsy
    Muchtar, Eli
    Buadi, Francis K.
    Gonsalves, Wilson I.
    Dingli, David
    Go, Ronald S.
    Warsame, Rahma
    Kourelis, Taxiarchis
    Lust, John A.
    Lacy, Martha Q.
    Dispenzieri, Angela
    Hayman, Suzanne R.
    Hwa, Yi
    Fonder, Amie
    Hobbs, Miriam
    Leung, Nelson
    Rajkumar, S. Vincent
    Gertz, Morie A.
    Wolfe, Eric
    [J]. BLOOD, 2018, 132
  • [49] Carfilzomib, lenalidomide, and low-dose dexamethasone in elderly patients with newly diagnosed multiple myeloma
    Dytfeld, Dominik
    Jasielec, Jagoda
    Griffith, Kent A.
    Lebovic, Daniel
    Vesole, David H.
    Jagannath, Sundar
    Al-Zoubi, Ammar
    Anderson, Tara
    Detweiler-Short, Kristen
    Stockerl-Goldstein, Keith
    Ahmed, Asra
    Jobkar, Terri
    Durecki, Diane E.
    McDonnell, Kathryn
    Mietzel, Melissa
    Couriel, Daniel
    Kaminski, Mark
    Vij, Ravi
    Jakubowiak, Andrzej J.
    [J]. HAEMATOLOGICA, 2014, 99 (09) : E162 - E164
  • [50] Safety and Efficacy of the Combination of Selinexor, Lenalidomide and Dexamethasone (SRd) in Patients with Newly Diagnosed Multiple Myeloma
    White, Darrell J.
    Lentzsch, Suzanne
    Gasparetto, Cristina
    Bahlis, Nizar
    Chen, Christine I.
    Lipe, Brea C.
    Schiller, Gary J.
    Tuchman, Sascha A.
    Sutherland, Heather J.
    Kotb, Rami
    Leblanc, Richard
    Sebag, Michael
    Venner, Christopher P.
    Callander, Natalie Scott
    Bensinger, William I.
    Sheehan, Heidi
    Chai, Yi
    Kai, Kazuharu
    Shah, Jatin
    Shacham, Sharon
    Kauffman, Michael G.
    Baljevic, Muhamed
    [J]. BLOOD, 2019, 134
12345